Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.66 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.66 |
| ▸ | ERBB4 | Q15303 | 3/20 | 0.66 |
| ▸ | KIT | P10721 | 2/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.66 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.66 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.66 |
| ▸ | CIT | O14578 | 1/20 | 0.66 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.66 |
| ▸ | GAK | O14976 | 1/20 | 0.66 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.66 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.66 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.66 |
| ▸ | STK17B | O94768 | 1/20 | 0.66 |
| ▸ | STK10 | O94804 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | LCK | P06239 | 1/20 | 0.66 |
| ▸ | FYN | P06241 | 1/20 | 0.66 |
| ▸ | YES1 | P07947 | 1/20 | 0.66 |
| ▸ | LYN | P07948 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30579743 | 1.00 | EGFR (0.66) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL30564570 | 0.82 | EGFR (0.61) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL2907710 | 0.82 | EGFR (0.61) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL27471165 | 0.82 | EGFR (0.57) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL14040940 | 0.81 | EGFR (0.81) | EGFRERBB2ERBB4KITSRC | |
| SCHEMBL28454175 | 0.80 | EGFR (0.49) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29623482 | 0.79 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29655741 | 0.79 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL29368458 | 0.79 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC | |
| Canertinib SCHEMBL54837 | 0.79 | EGFR (1.00) | EGFRERBB2ERBB4KITSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023173170-A1 | USE OF 4-THIAZOL-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES IN COMBINATION THERAPIES FOR CANCER | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-09-21 | — | — | WO | disclosed |
| EP-2817313-A1 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| EP-2632923-A1 | QUINAZOLINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-09-04 | — | — | EP | disclosed |
| WO-2013124025-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
| EP-2513066-A1 | SPHINGOSINE KINASE INHIBITORS | Merck Patent GmbH (DE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012055466-A1 | QUINAZOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-05-03 | — | — | WO | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| EP-2007811-A2 | TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF | AstraZeneca AB (SE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007120693-A2 | TARGETED BINDING AGENTS DIRECTED TO UPAR AND USES THEREOF | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1272188-A2 | USE OF EGFR TYROSINE KINASE INHIBITORS FOR TREATING BRESTA CANCER | The University of Manchester (GB) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001032155-A2 | USE OF EGFR TYROSINE KINASE INHIBITORS FOR TREATING BREAST CANCER | THE UNIVERSITY OF MANCHESTER (GB) | 2001-05-10 | — | — | WO | disclosed |